Our recent study shows that HDAC inhibitors (VPA, SAHA, and MS-275) increase CD133 significantly in neuroblastoma cell lines that do not show methylated its CpG promoters and VPA treatment may increase CD133+ cells that show higher resistance to cytostatics than CD133− cells. This evidence concerns the gene HDAC9 and neuroblastoma.